P4‐128: Low Prevalence of Amyloid Positivity in Healthy Elderly Participants of a Methodology Study Evaluating Remote Tablet‐Based Cognitive Learning
Claire Leurent(Pfizer (United States)), Robert Alexander(Pfizer (United States)), Sridhar Duvvuri(Cerevel Therapeutics (United States)), James Goodman(Cambridge University Hospitals NHS Foundation Trust), Jerome Barakos(Sutter Health), Scott Kellogg(Active Technologies (Italy)), Ping He(Guangdong Pharmaceutical University), Gregory Klein(Roche (Switzerland)), James W. Kupiec(Cassava Sciences (United States)), Eddie Martucci(Active Technologies (Italy)), Eve H. Pickering(Pfizer (United States)), Derek Purcell(BioClinica (United States))
Cited by 0
Related Papers
A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease
|Neurology|2009|741
11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study
|The Lancet Neurology|2010|696
Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease
|JAMA Neurology|2021|602
A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease
|Alzheimer s Research & Therapy|2017|568